S-2E is a compound that functions as an orally active, noncompetitive inhibitor of both HMG-CoA reductase and acetyl-CoA carboxylase. It exhibits an anti-hyperlipidemic action, making it suitable for studying conditions such as familial hypercholesterolemia and mixed hyperlipidemia [1] [2].

In the liver, S-2E undergoes conversion to its active form, S-2E-CoA, which noncompetitively blocks the function of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase, with inhibition constants (K i) of 18.11 μM and 69.2 μM, respectively [1]. When administered orally at doses ranging from 3 to 30 mg/kg, S-2E effectively reduces the secretion rates of very-low-density lipoprotein (VLDL)-cholesterol and triglycerides in rats treated with Triton WR-1339. Additionally, S-2E simultaneously decreases the levels of total cholesterol and triglycerides in the blood of Zucker fatty rats [1].